Travis <span>A.</span> Gerke
Researcher

Travis A. Gerke

Overview

Discipline

    • Cancer Epidemiology
    • Genitourinary Oncology
    • Cancer Epidemiology Program

Education & Training

    • Harvard University, AM - Biostatistics
    • Harvard School of Public Health, Sc.D.
Research

My active line of research lies in integrative molecular prostate cancer epidemiology, and is driven by concurrent interests in biostatistical methods development and computational biology. Several of my recent publications investigate tumor-based biomarkers that can distinguish aggressive from non-aggressive prostate cancers in large prospective cohorts. My methodological interests in this area concern ways in which high-dimensional data analysis techniques can be modified to discover markers that are highly specific for indolent cancer types. With regard to computational biology and statistics, I also collaborate on efforts to streamline processing, analysis, and epidemiologic translation of large-scale genomic databases such as The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus. Finally, an emerging research interest of mine applies contemporary methods in causal inference to existing clinical trial data in order to discover optimal treatment sequences for metastatic castration-resistant prostate cancer.

Publications

  • Zareba P, Flavin R, Isikbay M, Rider JR, Gerke TA, Finn S, Pettersson A, Giunchi F, Unger RH, Tinianow AM, Andersson SO, Andrén O, Fall K, Fiorentino M, Mucci LA. Perineural Invasion and Risk of Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):719-726. Pubmedid: 28062398. Pmcid: PMC5413395.
  • Mucci LA, Pernar CH, Peisch S, Gerke T, Wilson KM. Prostate cancer incidence as an iceberg. Eur J Epidemiol. 2017 May. Pubmedid: 28560536.
  • Pettersson A, Gerke T, Fall K, Pawitan Y, Holmberg L, Giovannucci EL, Kantoff PW, Adami HO, Rider JR, Mucci LA. The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies. Cancer. 2017 May;123(9):1490-1496. Pubmedid: 28152172.
  • Stopsack KH, Gerke TA, Andrén O, Andersson SO, Giovannucci EL, Mucci LA, Rider JR. Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis. 2017 Jun. Pubmedid: 28595267.
  • Wang K, Chen X, Bird VY, Gerke TA, Manini TM, Prosperi M. Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases. Int J Cancer. 2017 Jul. Pubmedid: 28699177.
  • Fankhauser CD, Mucci LA, Gerke TA. Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017;71:907-12. Eur Urol. 2017 Jul;72(1):e9-e10. Pubmedid: 28108146.
  • Ebot EM, Gerke T, Labbé DP, Sinnott JA, Zadra G, Rider JR, Tyekucheva S, Wilson KM, Kelly RS, Shui IM, Loda M, Kantoff PW, Finn S, Vander Heiden MG, Brown M, Giovannucci EL, Mucci LA. Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer. 2017 Jul. Pubmedid: 28700821.
  • Sinnott JA, Peisch S, Tyekucheva S, Gerke TA, Lis RT, Rider JR, Fiorentino M, Stampfer MJ, Mucci LA, Loda M, Penney KL. Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res. 2017 Jan;23(1):81-87. Pubmedid: 27663590. Pmcid: PMC5215643.
  • Waniga HM, Gerke T, Shoemaker A, Bourgoine D, Eamranond P. The Impact of Revised Discharge Instructions on Patient Satisfaction. J Patient Exp. 2016 Sep;3(3):64-68. Pubmedid: 28725840. Pmcid: PMC5513645.
  • Conboy L, Gerke T, Hsu KY, St John M, Goldstein M, Schnyer R. The Effectiveness of Individualized Acupuncture Protocols in the Treatment of Gulf War Illness: A Pragmatic Randomized Clinical Trial. PLoS One. 2016 Mar;11(3):e0149161. Pubmedid: 27031099. Pmcid: PMC4816551.
  • Lu D, Sinnott JA, Valdimarsdóttir U, Fang F, Gerke T, Tyekucheva S, Fiorentino M, Lambe M, Sesso HD, Sweeney CJ, Wilson KM, Giovannucci EL, Loda M, Mucci LA, Fall K. Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clin Cancer Res. 2016 Feb;22(3):765-772. Pubmedid: 26490316. Pmcid: PMC4738177.
  • Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2016 Feb;108(2). Pubmedid: 26615022. Pmcid: PMC4862436.
  • Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR. Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Res. 2016 Aug;76(16):4785-4790. Pubmedid: 27325648. Pmcid: PMC4987257.
  • Preston MA, Batista JL, Wilson KM, Carlsson SV, Gerke T, Sjoberg DD, Dahl DM, Sesso HD, Feldman AS, Gann PH, Kibel AS, Vickers AJ, Mucci LA. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol. 2016 Aug;34(23):2705-2711. Pubmedid: 27298404. Pmcid: PMC5019757.
  • Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, Pettersson A, Loda M, Sesso HD, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Heiden MV, Mucci LA. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer Metab. 2016;4:22. Pubmedid: 27980733. Pmcid: PMC5142400.
  • Terry RS, Gerke T, Mason JB, Sorensen MD, Joseph JP, Dahm P, Su LM. Postoperative rhabdomyolysis following robotic renal and adrenal surgery: a cautionary tale of compounding risk factors. J Robot Surg. 2015 Sep;9(3):195-200. Pubmedid: 26531199.
  • Martin NE, Gerke T, Sinnott JA, Stack EC, Andrén O, Andersson SO, Johansson JE, Fiorentino M, Finn S, Fedele G, Stampfer M, Kantoff PW, Mucci LA, Loda M. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res. 2015 Oct;13(10):1431-1440. Pubmedid: 26124442. Pmcid: PMC4618038.
  • Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, Giovannucci EL, Loda M, Mucci LA, Finn S. Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis. 2015 Jun;36(6):639-647. Pubmedid: 25863129. Pmcid: PMC4481603.
  • Sinnott JA, Rider JR, Carlsson J, Gerke T, Tyekucheva S, Penney KL, Sesso HD, Loda M, Fall K, Stampfer MJ, Mucci LA, Pawitan Y, Andersson SO, Andrén O. Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis. 2015 Jun;36(6):632-638. Pubmedid: 25870172. Pmcid: PMC4572920.
  • Shui IM, Mondul AM, Lindström S, Tsilidis KK, Travis RC, Gerke T, Albanes D, Mucci LA, Giovannucci E, Kraft P. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer. 2015 Jun;121(12):1949-1956. Pubmedid: 25731953. Pmcid: PMC4457645.
  • Penney KL, Sinnott JA, Tyekucheva S, Gerke T, Shui IM, Kraft P, Sesso HD, Freedman ML, Loda M, Mucci LA, Stampfer MJ. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):255-260. Pubmedid: 25371445. Pmcid: PMC4294966.
  • Gerke TA, Martin NE, Ding Z, Nuttall EJ, Stack EC, Giovannucci E, Lis RT, Stampfer MJ, Kantoff PW, Parmigiani G, Loda M, Mucci LA. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. Prostate. 2015 Dec;75(16):1926-1933. Pubmedid: 26469352. Pmcid: PMC4831584.
  • Shui IM, Lindström S, Kibel AS, Berndt SI, Campa D, Gerke T, Penney KL, Albanes D, Berg C, Bueno-de-Mesquita HB, Chanock S, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giles GG, Henderson B, Hoover R, Johansson M, Le Marchand L, Ma J, Navarro C, Overvad K, Schumacher FR, Severi G, Siddiq A, Stampfer M, Stevens VL, Travis RC, Trichopoulos D, Vineis P, Mucci LA, Yeager M, Giovannucci E, Kraft P. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014 Jun;65(6):1069-1075. Pubmedid: 24411283. Pmcid: PMC4006298.
  • Bismar TA, Alshalalfa M, Petersen LF, Teng LH, Gerke T, Bakkar A, Al-Mami A, Liu S, Dolph M, Mucci LA, Alhajj R. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome. BJU Int. 2014 Feb;113(2):309-319. Pubmedid: 24006850.